Pfizer posts another haemophilia hit
The group is taking marstacimab to the regulators, but Novo’s MAb looks like a bad omen.
Sanofi seeks to build on COPD win
Full Dupixent data confirm the drug’s blockbuster potential in the lung disease, but the French drug maker is thinking even bigger.
Scribe signs another big pharma deal
Lilly is the latest group, after Biogen and Sanofi, to collaborate on Scribe’s novel approach to Crispr editing.
ESPID 2023 – hospitalisation data in tune for Beyfortus
The Harmonie trial shows a hospitalisation benefit where Melody could not.
2023’s biggest launches: the story so far
Alzheimer’s has already grabbed attention but plenty of big regulatory decisions still loom for Sarepta, Crispr, Astellas and more.
A blockbuster year could be building
If forecasts prove accurate 2023 could be the biggest year for blockbuster launches for some time.
